IN BRIEF: NetScientific's portfolio company updates on cancer trial lse.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lse.co.uk Daily Mail and Mail on Sunday newspapers.
NetScientific investee claims promising results in biomarker study lse.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lse.co.uk Daily Mail and Mail on Sunday newspapers.
PDS Biotechnology Corp. (PDSB) announced interim safety and immune response data for the first-in-human Phase 1/2 clinical trial evaluating PDS0301, an investigational tumor-targeting, antibody-conjugated Interleukin 12, in combination with current standard-of-care chemotherapy, docetaxel, to treat metastatic castration sensitive and castration resistant prostate cancer.
NetScientific PLC - London-based deep tech and life sciences-focused venture capital investment company - Reports that its portfolio company, PDS Biotechnology Corp, has announced updated interim.